CVRx Inc
NASDAQ:CVRX
Intrinsic Value
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. [ Read More ]
The intrinsic value of one CVRX stock under the Base Case scenario is 15.924 USD. Compared to the current market price of 14.695 USD, CVRx Inc is Undervalued by 8%.
Valuation Backtest
CVRx Inc
Run backtest to discover the historical profit from buying and selling CVRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
CVRx Inc
Current Assets | 112.1m |
Cash & Short-Term Investments | 90.6m |
Receivables | 7.6m |
Other Current Assets | 14m |
Non-Current Assets | 3.1m |
PP&E | 3.1m |
Other Non-Current Assets | 27k |
Current Liabilities | 7.9m |
Accounts Payable | 1.9m |
Accrued Liabilities | 5.9m |
Other Current Liabilities | 125k |
Non-Current Liabilities | 31.4m |
Long-Term Debt | 29.2m |
Other Non-Current Liabilities | 2.2m |
Earnings Waterfall
CVRx Inc
Revenue
|
39.3m
USD
|
Cost of Revenue
|
-6.3m
USD
|
Gross Profit
|
33m
USD
|
Operating Expenses
|
-76.1m
USD
|
Operating Income
|
-43.1m
USD
|
Other Expenses
|
1.9m
USD
|
Net Income
|
-41.2m
USD
|
Free Cash Flow Analysis
CVRx Inc
CVRX Profitability Score
Profitability Due Diligence
CVRx Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
CVRx Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
CVRX Solvency Score
Solvency Due Diligence
CVRx Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
CVRx Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CVRX Price Targets Summary
CVRx Inc
According to Wall Street analysts, the average 1-year price target for CVRX is 33.15 USD with a low forecast of 30.3 USD and a high forecast of 36.75 USD.
Ownership
CVRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CVRX Price
CVRx Inc
Average Annual Return | -2.21% |
Standard Deviation of Annual Returns | 75.82% |
Max Drawdown | -83% |
Market Capitalization | 306.8m USD |
Shares Outstanding | 20 927 700 |
Percentage of Shares Shorted | 6.66% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
Contact
IPO
Employees
Officers
The intrinsic value of one CVRX stock under the Base Case scenario is 15.924 USD.
Compared to the current market price of 14.695 USD, CVRx Inc is Undervalued by 8%.